Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm, Residual 1

Interventions

palbociclib 2Trastuzumab 2Capecitabine 2trastuzumab deruxtecan 1tetrathiomolybdate 1sacituzumab govitecan 1pembrolizumab 1niraparib 1inavolisib 1giredestrant 1eribulin 1avelumab 1atezolizumab 1abemaciclib 1Zymosan 1Radiotherapy 1Letrozole 1Immunotherapy 1Hydroxychloroquine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × tetrathiomolybdate × Breast × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡